Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Electronic Arts Inc. (EA) vs ResMed Inc. (RMD) Price & Performance

Electronic Arts Inc.Trade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Electronic Arts Inc. vs ResMed Inc. — how do they compare? Electronic Arts Inc. trades at $207.26 (market cap $51.97B), while ResMed Inc. trades at $200.85 (market cap $28.80B). The key difference: Electronic Arts Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.

EARMD
Market Cap
$51.97B$28.80B
Sector
TechnologyHealth
52-Week High
$207.27$293.73
52-Week Low
$147.79$182.82
Enterprise Value
$50.54B$27.99B
Dividend Yield
0.37%1.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Electronic Arts Inc.

Electronic Arts (EA) trades at $206.65, showing modest daily gains of 0.15%. The stock exhibits a bullish technical structure with moving averages aligned positively, though oscillators signal caution with RSI levels above 70. Fundamentally, EA maintains strong profitability with 78.97% gross margins and 11.78% net income margins, but valuation metrics appear elevated with a P/E of 59.05 and P/S of 6.96. Recent business developments include the successful launch of EA SPORTS College Football 27 and the introduction of EA Advertising platform for in-game brand integration.

The outlook balances strong franchise execution against valuation concerns. Investment opportunities stem from EA's dominant gaming portfolio, recurring revenue streams, and new advertising monetization. Key risks include recent earnings misses, potential regulatory scrutiny of the rumored $55 billion Saudi acquisition (Reuters, June 24, 2026), and stretched valuation multiples that may limit near-term upside despite analyst consensus leaning positive.

ResMed Inc.

ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.

RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Electronic Arts Inc.

EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.

Read more on EA

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD